Excerpt from Conflict of Interest, Protection of Public Ownership, in Drug Development Deals Between Tax-Exempt, Federally Supported Labs and the Pharmaceutical Industry: Hearing Before the Subcommittee on Regulation, Business Opportunities, and Technology of the Committee on Small Business House Representatives One Hundred Third Congress, First Session, Washington, DC, March 11, 1993
We are very pleased that she is sitting in. I would like to recog nize her for any comments that she would like to make.
About the Publisher
Forgotten Books publishes hundreds of thousands of rare and classic books. Find more at www.forgottenbooks.com
This book is a reproduction of an important historical work. Forgotten Books uses state-of-the-art technology to digitally reconstruct the work, preserving the original format whilst repairing imperfections present in the aged copy. In rare cases, an imperfection in the original, such as a blemish or missing page, may be replicated in our edition. We do, however, repair the vast majority of imperfections successfully; any imperfections that remain are intentionally left to preserve the state of such historical works.
Die Inhaltsangabe kann sich auf eine andere Ausgabe dieses Titels beziehen.
Anbieter: Forgotten Books, London, Vereinigtes Königreich
Paperback. Zustand: New. Print on Demand. This book is a discussion of the conï ict of interest, protection of public ownership, in drug development deals between tax-exempt, federally supported labs, and the pharmaceutical industry. The author discusses the history of this collaboration and the potential importance to public health of this medical research collaboration. The author then turns to the experience of private, nonproï t research labs, some in universities, and some independent, receiving signiï cant, if not a majority, of their annual operating budget through federal grants. Of special interest to the author is instances where private, nonproï t research institutes sign exclusive technology transfer agreements with private drug companies. The author discusses how such agreements can be extremely detrimental to small business because they create monopolies dominated by very large multinational pharmaceutical corporations that reduce market place competition in the United States, decreasing market access for small companies, and probably encouraging higher drug prices for consumers. This book is a reproduction of an important historical work, digitally reconstructed using state-of-the-art technology to preserve the original format. In rare cases, an imperfection in the original, such as a blemish or missing page, may be replicated in the book. print-on-demand item. Bestandsnummer des Verkäufers 9781332256341_0
Anzahl: Mehr als 20 verfügbar
Anbieter: PBShop.store US, Wood Dale, IL, USA
PAP. Zustand: New. New Book. Shipped from UK. Established seller since 2000. Bestandsnummer des Verkäufers LW-9781332256341
Anbieter: PBShop.store UK, Fairford, GLOS, Vereinigtes Königreich
PAP. Zustand: New. New Book. Shipped from UK. Established seller since 2000. Bestandsnummer des Verkäufers LW-9781332256341
Anzahl: 15 verfügbar
Anbieter: Buchpark, Trebbin, Deutschland
Zustand: Sehr gut. Zustand: Sehr gut | Seiten: 264 | Sprache: Englisch | Produktart: Bücher | Keine Beschreibung verfügbar. Bestandsnummer des Verkäufers 26069493/2
Anzahl: 1 verfügbar